[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"controlled-ovarian-simulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:controlled-ovarian-simulation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100592781","phase-2-menopur-and-rekovelle-combination-study-version-20-100592781",false,"NCT06997900","Menopur And Rekovelle Combination Study Version 2.0","MARCS 2","Inclusion Criteria:\n\n* Women aged 18 to 40 years inclusively at the time of consent form signature\n* Diagnosis of unexplained infertility, tubal infertility, endometriosis stage I\u002FII or male factor infertility\n* Regular menstrual cycles of 24-35 days\n* Presence of both ovaries\n* Early follicular phase FSH serum concentration \\\u003C10 IU\u002FL measured between Day 2 and Day 5 of menstrual cycle within the previous 24 months\n* First IVF\u002FICSI cycle\n* IVF antagonist protocol prescribed\n* Partner or donor ejaculated sperm (fresh or frozen) used for fertilization\n\nExclusion Criteria:\n\n* Women undergoing oocyte donation\n* Endometriosis stage III\u002FIV\n* High risk of OHSS (AMH ≥ 35 pmol\u002FL)\n* Body Mass Index (BMI) \\> 40 kg\u002Fm2 Protocol number: IIS-1056 MARCS 2.0 Study Version: 1.1 - Date : 14 APR 2025 Page 12 of 28\n* Gynaecological haemorrhages of unknown aetiology\n* History of recurrent miscarriages defined as ≥ 3 consecutive losses\n* Renal or hepatic impairment\n* Hypersensitivity to any active ingredient or excipients in follitropin delta and\u002For HP-hMG\n* Tumours of hypothalamus or pituitary gland\n* Ovarian enlargement or ovarian cyst not due to polycystic ovarian syndrome\n* Current or history of ovarian, uterine or mammary carcinoma\n* History of thrombophilia\n* Use of hormonal preparations (except for 17β-estradiol, testosterone gel, DHEA and thyroid medication) during the last menstrual cycle\n* Women participating in any other interventional research project","FEMALE","18 Years","40 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to evaluate the safety and effectiveness of a personalized ovarian stimulation regimen in women aged 18 to 40 undergoing in vitro fertilization (IVF). The main question it aims to answer is:\n\n\\- Does personalizing the starting doses of follitropin delta (REKOVELLE) and HP-hMG (MENOPUR) based on both age and body lead to similar results as anti-Müllerian hormone (AMH) and weight based dosing ?\n\nResearchers will compare the new dosing regimen to the MARCS study results to see if this new approach leads to similar outcomes\n\nParticipants will:\n\n* Receive ovarian stimulation using a personalized dose of REKOVELLE aND MENOPUR based on age and weight\n* Be monitored through ultrasound imaging and blood tests to measure estradiol (E2) levels\n* Undergo standard IVF procedures including egg retrieval and embryo assessment",[27,28,29],"IVF","Controlled Ovarian Simulation","Fertility Disorders","RECRUITING","2025-07-29",{"date":33,"type":34},"2025-07-31","ACTUAL",{"date":36,"type":34},"2025-07-04",{"date":38,"type":21},"2027-08",{"name":40,"class":41},"Clinique Ovo","INDUSTRY",2]